This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Krause, I Articles by Shoenfeld, Y Search for Related Content PubMed PubMed Citation Articles by Krause, I Articles by Shoenfeld, Y Social Bookmarking                         What's this?

Anti-endothelial cell antibodies in the sera of hyperprolactinemic women

Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer

Z Blumenfeld

Department of Obstetrics and Gynecology, Rambam Medical Center, Technion Faculty of Medicine, Haifa

M Malchinsky

S Cohen

M Blank

Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer

A Eldor

Institute of Hematology, Sorasky Medical Center, Tel-Aviv, Israel

B Weksler

Cornell University Medical College, NY, USA

K Schweitzer

Free University, Amsterdam, The Netherlands

Y Shoenfeld

Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer

Prolactin (PRL) is closely associated with autoimmune diseases in animal models and humans, and several disease-related autoantibodies were reported in increased titers in patients with hyperprolactinemia (HPRL). We studied the presence of anti-endothelial cell antibodies (AECA) and other autoantibodies in sera of female patients with HPRL. Sera from 25 HPRL patients and 10 healthy female controls were tested for AECA (against both macrovascular and microvascular endothelial cell antigens), anti-dsDNA, and anti-cardiolipin (anti-CL) using ELISA. Sera were considered positive for the autoantibody when the optical density (OD) value was more than 3 s.d. above the mean of the OD in normal controls. Sera from 13 patients were obtained repeatedly during dopaminergic anti-PRL treatment, to relate PRL level or anti-PRL treatment with the autoantibody levels. Elevated micro and/or macrovascular AECA were observed in sera from 19=25 patients (76%). Elevated titers of anti-CL Abs, all b2-GPI-dependent, and low levels of anti-dsDNA antibodies (Abs) were also observed in the HPRL patients. Inhibition studies showed that the affinity purified AECAs bound the endothelial cell (EC) antigens in a dose-dependent manner. Titers of AECA as well as anti-DNA and anti-CL autoantibodies did not correlate with PRL level nor with the use or duration of anti-PRL treatment. None of the HPRL patients presented clinical manifestations of autoimmune disease. We conclude that elevated levels of AECA as well as anti-DNA and anti-CL autoantibodies are frequent in hyperprolactinemia. Our results further support the association of PRL and autoimmunity, and may point to a relationship between AECA-associated diseases and HRPL. The presence of autoantibodies in patients with HPRL might portend an increased risk for future development of autoimmune disease.

Key Words: prolactin • autoimmunity • anti-endothelial cell antibodies • anti-DNA antibodies • anti-cardiolipin antibodies

Lupus, Vol. 7, No. 6, 377-382 (1998)
DOI: 10.1191/096120398678920316


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S E Walker and L.-y. Yu-Lee Overview: prolactin and autoimmunity Lupus, October 1, 2001; 10(10): 659 - 659. [PDF]

				A M Jacobi, W Rohde, M Ventz, G Riemekasten, G-R Burmester, and F Hiepe Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity Lupus, August 1, 2001; 10(8): 554 - 561. [Abstract] [PDF]

				A M Jacobi, W Rohde, H-D Volk, T Dorner, G-R Burmester, and F Hiepe Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls Ann Rheum Dis, March 1, 2001; 60(3): 242 - 247. [Abstract] [Full Text] [PDF]

				S E Walker, D Miller, D L Hill, and G R Komatireddy Prolactin, a pituitary hormone that modifies immune responses: Proceedings of the Mini-symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico Lupus, July 1, 1998; 7(6): 371 - 375. [PDF]